Clinical trials recruiting for Colorectal Adenocarcinoma

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
  NCT07291180 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 81 Years · Sex: All (male and female) · 1 location
• A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
  NCT06349044 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
  NCT07020117 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
  NCT06682793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
  NCT06051695 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
  NCT06951503 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• AK129 Combination Therapy for Advanced Solid Tumors
  NCT06943820 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies
  NCT06076811 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Early Detection of Advanced Adenomas and Colorectal Cancer
  NCT06342440 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Early Onset Colorectal Cancer Detection
  NCT06342401 · Phase: Not specified · Ages: 18 Years to 50 Years · Sex: All (male and female) · 13 locations
• Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
  NCT06640166 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Evaluation of Skin Tests in Biotherapy Allergies
  NCT06971848 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
  NCT06050447 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Family Communications After Genetic Testing
  NCT07143487 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 299 locations
• Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer
  NCT06225011 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes
  NCT06955767 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
  NCT04739072 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)
  NCT05988645 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)
  NCT07795749 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
  NCT03715933 · Phase: Phase 1 · Ages: 12 Years to 85 Years · Sex: All (male and female) · 36 locations
• Stage II/III Colorectal Cancer Recurrence
  NCT06314958 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
  NCT07407465 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations

Related conditions

Trials recruiting for Colorectal Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Colorectal Adenocarcinoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.